When new cells are needed to replace old, worn-out cells in our organs and tissues, the DNA that encodes the blueprint for all cellular components from one cell must be replicated faithfully in each...
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the approval of safe and effective anticancer therapies. With the increasing complexity of cancer-related policy issues,...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted therapeutics that can be used to treat patients with any type of cancer provided their...
Cervical cancer patients may benefit from addressing any stress disorders they might have, as it could potentially improve their cancer prognosis.
The AACR Project Genomics Evidence Neoplasia Information Exchange (AACR Project GENIE) is a unique registry that aggregates, harmonizes, and links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients....
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib (Piqray), polatuzumab vedotin-piiq (Polivy), selinexor (Xpovio), and darolutamide (Nubeqa)—for treating certain patients with a wide...
Cancer is very complex, and the tools that we need to understand how it develops and progresses come from many different scientific fields. Integrative Molecular Epidemiology, known as IME, brings together epidemiologists, data scientists,...
As a monthly staple on this blog, we feature the editors’ picks from the 10 journal issues published by the American Association for Cancer Research (AACR). This month, selections include two articles detailing laboratory...
A study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression of prostate cancer.
This spring, in the inaugural year of the American Association for Cancer Research (AACR) Global-Scholar-In-Training Awards (GSITA) program, 15 young researchers from around the world arrived in Atlanta eager to share their knowledge and...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More